2021 Summer GAPNA Newsletter Volume 40 Number 2

Analysis Shows Value of Vaccinating Older Adults, Young Children Against Norovirus

Vaccinating older adults and young children against norovirus can deliver significant clinical and economic benefits, according to a new study.

Vaccines are now in development against norovirus, which each year causes mild to severe gastrointestinal symptoms in about 20 million Americans.

The authors developed a computational simulation model of the spread of norovirus in different age groups within the U.S. population to better understand the value of vaccinating adults 65 years of age and older and children under 5 years old.

They found that, depending on vaccine efficacy and modeled population coverage, vaccinating all preschool-aged children could avert up to 72% of symptomatic norovirus cases in a community, and vaccinating all older adults could avert up to 29% of such cases.

More information

Access the abstract: Potential Clinical and Economic Value of Norovirus Vaccination in the Community Setting, to learn more.

View the Abstract